GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
Read more:
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Company’s Pure-Vu® GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.
See the original post:
Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, November 9, 2020.
Read this article:
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:
Read more:
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Tuesday, November 10, 2020. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
Go here to see the original:
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018.
See more here:
Abcam plc: Consultation on 2020 LTIP Awards
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on October 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
Originally posted here:
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONMOUTH JUNCTION, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/LYTENAVA™ (NORSE THREE). Patient enrollment for the study was completed in less than one month, significantly ahead of the planned four-month enrollment schedule.
See the original post here:
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at www.abcamplc.com.
See original here:
Abcam plc: Annual Report, Impact Report and Notice of AGM
Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET Live Webinar Featuring 3 KOLs Focused on Front and Back of the Eye Conditions and Opportunities for New Treatments on Monday, November 9, at 10:00am ET
Read more here:
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330